Sangamo reports updated data for gene therapy candidate ST-920
Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.
infectiousdiseaseadvisor.com6d
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
rheumatologyadvisor4d
Gamma Delta CAR T-Cell Therapy Fast Tracked for SLE With Extrarenal Involvement
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
Renal & Urology News6d
FDA Approves Clinical Trials for Pig Kidney Transplants in Humans
Cross-species transplantation will now be tested in human clinical trials in the US. (HealthDay News) — The US Food and Drug Administration (FDA) has approved the first-ever clinical trials ...
Medscape6d
The Use of Newer Antiepileptic Drugs in Patients With Renal Failure
Hemodialysis (HD)-related factors also alter drug clearance. Vigabatrin: in patients with renal impairment the dose should be decreased based on creatinine clearance. The effect of dialysis on ...
Medscape4d
Cardiovascular Risk in Renal Transplantation
Renal transplant patients suffer from a higher risk of cardiovascular morbidity and mortality. The risk-factor spectrum is different from the general population; several risk factors are ...
Business Wire6d
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
T cell therapy targeting CD20 for the treatment of autoimmune diseases. ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus ...
Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally
Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...
Crain's Chicago Business4d
AbbVie gets FDA OK on antibiotic therapy that fights resistant bacteria
The U.S. Food & Drug Administration approved the therapy in combination with metronidazole for patients 18 years and older who have limited or no alternative options for the treatment of ...
Pharm Exec6d
FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus
The FDA has awarded Fast Track Designation (FTD) Adicet Bio, Inc’s novel allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy ADI-001 for adults with refractory systemic lupus ...
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.
pharmaphorum5d
FDA approves Adstiladrin as first gene therapy for NMIBC
The application was granted Priority Review, Breakthrough Therapy, and Fast Track designations. The FDA approval makes Adstiladrin the first gene therapy to be approved for adult patients with ...